GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2013
Breast cancer, version 3.2013: featured updates to the NCCN guidelines.
Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Performance of [68Ga]Ga-FAPI PET in Breast, Ovarian, and Cervical Cancers: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2026Pooled it
- Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Annals of laboratory medicine · 2017Guideline
- The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review.Clinical drug investigation · 2016Pooled it
- DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Guideline
- Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial.Cancer communications (London, England) · 2025Trial
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Trial
- Trial
- Gallic Acid Enhances the Anticancer Activity of Docetaxel in Triple-Negative Breast Cancer Cells.Biology · 2026Article
- Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.International journal of breast cancer · 2026Article
- Catalase: The golden key to regulate oxidative stress in breast cancer.World journal of clinical oncology · 2025Review
- Article
- Receipt of guideline-concordant care and survival among young adult women with non-metastatic breast cancer.Breast cancer research and treatment · 2025Article
- MRI-based radiomics model for predicting tumor regression patterns after neoadjuvant chemotherapy in breast cancer.Frontiers in medicine · 2025Article
- Bilateral Primary Breast Cancer With Discordance in Molecular Subtypes: A Case Report.International journal of breast cancer · 2025Article
- Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer-A Single-Center Experience.Life (Basel, Switzerland) · 2024Article
- Benefits of adjuvant treatment with the Pingxiao capsule in patients with early breast cancer: A single‑center retrospective cohort study.Oncology letters · 2024Article
- Effect of progressive resistance exercise using Thera-band on edema volume, upper limb function, and quality of life in patients with breast cancer-related lymphedema.Journal of exercise rehabilitation · 2023Article
- Giant Malignant Phyllode Tumor: A Case Report.Cureus · 2022Article
- Use of Routine Health Datasets to Assess the Appropriateness of Diagnostic Tests in the Follow-Up of Breast Cancer Patients: A Population-Based Study on 3930 Patients.Risk management and healthcare policy · 2022Article
- Correlation of dynamic contrast-enhanced MRI and diffusion-weighted MR imaging with prognostic factors and subtypes of breast cancers.Frontiers in oncology · 2022Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.